Pfizer Claims Pharmaceutical's Latest Big Prize

The video discusses Pfizer's recent acquisitions, highlighting the $13.7 billion Medivation deal and the failed Allergan merger. It explores why oncology is a hot market for acquisitions, driven by scientific advancements and pricing dynamics. The potential split of Pfizer is debated, with analysts suggesting recent deals may not influence this decision. Other potential acquisition targets in the oncology space, such as Biomarin and Insight, are also mentioned.

What impact did the failed allergy deal have on Pfizer's acquisition strategy?

Which companies are mentioned as potential targets for Pfizer in the oncology space?